Published 1 day ago • loading... • Updated 1 day ago

Ataraxis AI to Transform Precision Medicine in Cancer Care with $20.4 Million Series A

Summary by Intelligence360 News

With new backing from AIX Ventures, Peter Thiel, and healthcare and AI pioneers, Ataraxis AI is positioned to rapidly bring its first offering, Ataraxis Breast, to market March 05, 2025 02:13 PM Eastern Standard Time NEW YORK–(BUSINESS WIRE)–Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann …

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

AllBlogThings.com - A Tech & Business Blog!

AI in Biotech: Enhancing Precision Medicine and Personalized Treatments

The era of one-size-fits-all medicine is ending. Today, treatments are increasingly shaped by individual biology - your genes, metabolism, even your microbiome. But tailoring therapies requires analyzing vast, complex datasets. Enter AI: not as a replacement for doctors, but as a tool to decode patterns humans can't see. Here's how it's transforming precision medicine. AI Accelerates Targeted Therapies Consider rare genetic disorders. Traditiona…

1 day ago

Read Full Article